1. RANBAXY
SUBMITTED BY: CHAITANYA S SALUNKE.
DIV : CORE C.
ROLL NO :049.

2. RANBAXY
Ranbaxy Laboratories Limited (Ranbaxy) is a research based
international pharmaceutical company serving customers in over 150
countries. For more than 50 years, it has been providing high quality,
affordable medicines trusted by healthcare professionals and patients
across geographies.
Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a
leading global pharma innovator, headquartered in Tokyo, Japan.
It has ground operations in 43 countries and 16 manufacturing
facilities spread across 8 countries. It has also covered all the top 25
pharmaceutical markets of the world and has a robust presence across
both developed and emerging markets.

3. Offering High Quality, Affordable Pharmaceuticals:
Ranbaxy is a vertically integrated company that develops,
manufactures and markets Generic, Branded Generic, Value-added and
Over-the-Counter (OTC) products, Anti-retrovirals (ARVs), Active
Pharmaceutical Ingredients (APIs), and Intermediates. It has a large
portfolio of over 500 molecules that cover multiple dosage forms including
tablets, capsules, injectables, inhalers, ointments, creams and liquids. Their
presence extends across therapies and includes Anti-infectives,
Cardiovascular, Pain management, Central Nervous System (CNS),
Gastrointestinal, Respiratory, Dermatology, Orthopaedics, Nutritionals and
Urology. Biotech and Vaccines are two new segments that we have begun
investing in. A stronger presence in these areas will add significant depth to
the existing product pipeline.
Through their unique hybrid business model involving Daiichi
Sankyo, they also introduce innovator products in markets around the
world.
Driven by Innovation:
Their continued focus on Research & Development (R&D) has
resulted in several regulatory approvals in both developed and emerging
markets. They have multiple R&D centres in Gurgaon, Haryana, India with
facilities for generic and innovative research. Their scientists have given
India its first New Chemical Entity (NCE) that was launched on April 25,
2012. The product, SynriamTM, is a new age cure for Malaria. With a
strong focus on research in generics, they are increasingly working on
more complex and specialised areas.
Delivering Value:

4. Their business philosophy, based on delivering value to our
stakeholders, constantly inspires our people to innovate, excel and
set new global benchmarks. Their multicultural workforce,
comprising more than 14,600 employees of over 50 nationalities, gives
them the strength to make quality healthcare accessible to people around
the world. They remain committed to aggressively pursuing their mission
of ‘Enriching lives globally, with quality and affordable pharmaceuticals’.
Mission:
Enriching lives globally, with quality and affordable pharmaceuticals
Values:
1. Achieving customer satisfaction is fundamental to the business
2. Provide products and services of the highest quality
3. Practice dignity and equity in relationships and provide
opportunities for the people to realise their full potential
4. Ensure profitable growth and enhance wealth of the shareholders
5. Foster mutually beneficial relations with all the business partners
6. Manage the operations with high concern for safety and environment
7. Be a responsible corporate citizen
Top Products of Ranbaxy:
Molecule Drug Class
Atorvastatin & Combinations Hypolipidemics
Donepezil Anti-Alzheimer’s
Valacyclovir Anti-Virals
Simvastatin Hypolipidemics
Amoxicillin+Clavulanic Acid Anti-bacterials
Ketorolac Analgesics
Ciprofloxacin & Combinations Anti-bacterials
Imipenem + Cilastatin Anti-bacterials

5. Loratadine& Combinations Anti-histaminics
Fenofibrate& Combinations Hypolipidemics
Amoxicillin & Combinations Anti-bacterials
Cephalexin Anti-bacterials
Clarithromycin Anti-bacterials
Ambazone Oral Antiseptics
Pantoprazole & Combinations Proton Pump Inhibitor
THERAPIES:
Anti – Infectives
Ranabaxy has a significant presence in the Anti-infectives segment
having leadership position in key markets in Penicillins, Cephalosporins,
Macrolides, Flouroquniolones, Anti-fungals, Anti-virals, Anti-retrovirals
(ARVs) and critical care. Their leading molecules in this segment are
Valacyclovir, Amoxicillin + Clavulanic Acid, Ciprofloxacin, Imipenem +
Cilasatin and Amoxicillin. Besides India, the other important markets
where they have a strong presence in this segment are the US, South Africa,
Russia, France, Germany, Romania, Brazil, Poland, Thailand and Malaysia.
Penems form an important part of our portfolio. They sell Imipenem +

6. Cilastatin in more than 50 countries. On April 25, 2012, they
launched India’s first New Chemical Entity (NCE), SynriamTM, for
the treatment of uncomplicated falciparum malaria. It is a fixed
dose combination of Arterolane 150 mg and Piperaquine 750 mg.
Cardio –Vascular
Cardiovascular (CVS) ailments are on the rise all over the world due
to changing lifestyles. As a result, there is an increasing need for CVS drugs.
Ranbaxy has been at the forefront of developing affordable, quality drugs
for various CVS ailments like Hyperlipidemia, Hypertension and Diabetes.
Strengthening the global leadership in statins, they launched their generic
version of the world’s largest selling drug (Atorvastatin) in the US as a
First-to-File (FTF) product. Today, Atorvastatin is marketed by us in more
than 25 countries worldwide, including the US, India, Canada, Romania,
South Africa, Australia and Malaysia. In markets like India, Romania,
Russia, South Africa and Malaysia, Ranbaxy is among the leading companies

7. selling Simvastatin, Rosuvastatin, Aspirin, Losartan and Acarbose
formulations.
Pain and Muskuloskeletal
Some of their best-selling molecules in the Pain and Musculoskeletal
segment are Ketorolac, Diclofenac, Paracetamol and Ibuprofen
combinations. They have launched specialised products like Cox 2
inhibitors for Osteoarthritis in several markets and are working on various
specialised molecules to cater to this growing segment.
Gastro-intestinal

8. Gastrointestinal is another significant therapeutic segment for
Ranbaxy. Proton pump inhibitor (PPI) drugs for the treatment of ulcers are
the leading drug class for them. In PPIs, like Pantoprazole, Rabeprazole,
Lansoprazole and Omeprazole, they are leaders in several markets. Besides
PPI, they have a strong presence in Ranitidine,H Pylori kits, Papain and
digestive enzyme formulations.
Respiratory
There is a growing global population of patients with ailments
relating to Chronic Obstructive Pulmonary Disease (COPD), which makes
this therapy an important focus area for them. Ranbaxy has a significant
presence in this segment, especially in the US, India, Eastern Europe, South
Africa and Latin America. Some of our leading products in this segment are

9. Ambazone, Loratadine combinations, Triamcinolone, Montelukast
and Fexofenadine.
Central Nervous System (CNS)
Ranbaxy has a wide portfolio of drugs for Central Nervous System (CNS)
ailments like Schizophrenia, Epilepsy, Depression, Neuropathic Pain,
Alzheimer’s Disease and Parkinson’s. Their leading molecules in CNS are
Donepezil, Sertraline, Gabapentin, Pentazocine and Olanzapine.
Anti–Retro Virals
Ranbaxy offers a wide range of World Health Organisation
prequalified (WHO PQ) Anti-retroviral (ARV) products that are supplied in

10. more than 100 countries in Africa, Latin America, CIS and Asia.
Close to a million patients worldwide use the ARV products as part
of the daily treatment regimen. Ranbaxy were among the first
generic companies to offer ARVs to various National AIDS treatment
programmes in Africa. Their ARV portfolio comprises Bio-equivalent Anti-
retroviral products and Anti-infectives. The products are manufactured at
our state-of-the-art facilities that have been approved by WHO PQ and/or
stringent regulatory authorities. ARVs are being procured for large
treatment programmes by major institutions such as Unicef, Global Fund –
Voluntary Pooled Programme (VPP) (through PFSCM), UNITAID/CHAI
(Clinton Health Access Initiative), Red Cross IDA, Missionpharma Crown
Agents, Population Services International and United Nations Development
Programme.
Dermatology :
Ranbaxy has a major focus in Dermatology with a presence across markets,
including the US, India and Brazil. They also have a robust franchise in the
Corticosteroids, Anti-infectives and Anti-acne segments. Their current
portfolio in the US caters to both prescription and consumer driven Over-

11. the-Counter (OTC) markets, the major brands being Ultravate,
Kenalog and Lac Hydrin. They have the global licensing rights to
market Luliconazole (a novel Anti-fungal) in 16 markets, including
India, Malaysia, Singapore and South Africa.
Over The Counter (OTC) Products:
Towards a Healthier World
Ranbaxy Global Consumer Healthcare (RGCH) is a separate business
division through which they develop and market Over-the-Counter (OTC)
products in more than 20 countries across Asia, Africa, the Middle East and
Europe. This division is one of our fastest growing and offers 15 products,
including some top-selling brands that have leadership status in their
respective segments. Some of our key OTC brands are Revital, Volini,
Faringosept, Aspenter and Chericof.
RGCH commenced its operations in 2002 with the launch of Pepfiz,
Gesdyp and Garlic Pearls in the Indian market. The portfolio was
strengthened with the addition of Revital. In 2005, Chericof was added to
the offering and, in 2007, Volini, a topical analgesic brand, was introduced.
Today, Revital, our flagship brand in the OTC segment, is India’s
largest selling Vitamins & Minerals Supplement. It is also among the Top 5
OTC brands of India. Volini is among the fastest growing pain relievers
available in India. It is also counted amongst the Top 10 brands in the
Indian pharmaceutical market. Some of our other key OTC brands are
Revital Woman, VoliniActiv and Revitalite.
Providing Innovative Healthcare Solutions
At RGCH, they strive relentlessly to enhance the well-being of
consumers by providing innovative healthcare solutions. They follow the

12. model of staying in constant touch with the market through
research and responding to its needs through appropriate products.
The division has an aggressive sales and distribution strategy that
involves penetrating Class II towns directly and smaller towns through the
‘hub and spoke’ model. They pursue a differentiated sales and distribution
strategy of engaging FMCG/OTC distributors for our OTC products. The
distribution infrastructure continues to grow, with about 1000+
distributors and sales representatives covering outlets that account for
more than 90% of category volumes for all our major OTC brands.
OTC Products
Brand name Generic name Therapeutic segment
REVITAL Ginseng, Vitamins and
Minerals
VMS-Vitamins, Minerals
and Supplements
REVITAL LIQUID Ginseng, Vitamins and
Minerals
VMS-Vitamins, Minerals
and Supplements
REVITAL WOMAN Ginseng, Vitamins and
Minerals
(Specially formulated for
women)
VMS-Vitamins, Minerals
and Supplements
REVITAL SENIOR Vitamins, Minerals, VMS-Vitamins, Minerals

13. Ginseng and Isoflavones
(Specially formulated for
50 years+)
and Supplements
REVITALITE Soy Protein Supplement VMS-Vitamins, Minerals &
Supplements
VOLINI GEL Pain relief Gel ANALGESIC-Topical
VOLINI SPRAY Pain relief Spray ANALGESIC-Topical
VOLINI ACTIV
GEL
Ayurvedic Pain relief Gel ANALGESIC-Topical
CHERICOF COUGH
SYRUP
Complete Cough Syrup for
family
CCA-Cough, Cold & Allergy
PEPFIZ Effervescent digestive
enzymes
GI-Gastrointestinal
GARLIC PEARLS Garlic oil for all round
health
GI-Gastrointestinal
GESDYP Digestive Enzymes GI-Gastrointestinal
OTC Products are Available Across Countries
India Russia Romania Africa
Vitamins &
Dietary
Supplements
Revital
Revital Woman
Revital Senior
Vitamins &
Dietary
Supplements
Revital Garlic
Pearls
Fenules
Heart Health
Aspenter
Aspacardin
Vitamins &
Dietary
Supplements
Revital
Riconia

14. Revitalite
Pain Relievers
Volini Gel & Spray
VoliniActiv
Pain Relievers
Brustan
Vitamins &
Dietary
supplements
Glubifer
Pain Relievers
Painamol
Brustan
Gastrointestinal
Remedies
Pepfiz
Garlic Pearls
Gesdyp
Gastrointestinal
Remedies
Pepfiz
Gastrointestinal
Remedies
Furazolidon
Gastrointestinal
Remedies
Pepfiz
Gestid
Vomidon
Cough & Cold
Remedies
Chericof
Cough & Cold
Remedies
Coldact Flu Plus
Faringosept
Cough & Cold
Remedies
Faringosept
Cough & Cold
Remedies
Rhineton
Chericof

15. 2013 Award
ASSOCHAM Innovation Excellence Platinum Award
Ranbaxy wins the ASSOCHAM Innovation Excellence Platinum Award for SynriamTM, a
new age cure for malaria
Golden Peacock Award
Ranbaxy wins the Golden Peacock Innovative Product/Service Award for SynriamTM, a
new age cure for malaria
2012
Frost & Sullivan Pharmaceutical Company of the Year
Ranbaxy wins the 2012 Frost & Sullivan Malaysia Excellence Award
for being adjudged the Malaysian Pharmaceutical Company of the Year in the Generics
Drug Category
Best Pharma Company for the year 2011 – Dun & Bradstreet

16. Ranbaxy is awarded the Best Pharma Company of the Year 2011 by
Dun & Bradstreet
2011
Padma Shri, the Fourth Highest Civilian Award in India, for Dr. NityaAnand,
Chairman of Ranbaxy Science Foundation
Dr. NityaAnand, Chairman of Ranbaxy Science Foundation, is
honoured by the President of India with the Padma Shri, the Fourth Highest Civilian
Award, in recognition of his notable performance in the field of drug research
The Economic Times IMEA 2011 – Gold Award in the Pharmaceuticals Sector
Ranbaxy wins the Economic Times IMEA 2011 – Gold Award in the
Pharmaceuticals Sector. The award is conceptualised and instituted by Frost and Sullivan
in collaboration with The Economic Times
New Jersey Business and Industry Association Award for Excellence
Ranbaxy is felicitated with the New Jersey Business and Industry
Association Award for Excellence in the Business Expansion Category
Brand of the Year 2011 Award for Revital and Volini

17. Ranbaxy bags ‘Brand of the Year 2011 Award for Revital and Volini’ at
the Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s
leading pharma magazine and the Indo-American Chamber of Commerce
India’s most Admired Nutrition and Neutraceuticals for Revital Woman
Ranbaxy wins Award for the Year 2011 for ‘India’s most Admired
Nutrition and Neutraceuticals’ for Revital Woman at the Pharmaceutical Leadership
Awards 2011 organised by Pharma Leaders, India’s leading pharma magazine and the
Indo-American Chamber of Commerce
Pharma OTC Company of the Year 2011
Ranbaxy is recognised as ‘Pharma OTC Company of the Year 2011′
for its Global Consumer Healthcare Division at the Pharmaceutical Leadership Awards
2011 organised by Pharma Leaders, India’s leading pharma magazine and the Indo-
American Chamber of Commerce
CSR Organisation of the Year 2011
Ranbaxy wins the title of ‘CSR Organisation of the Year 2011′ at the
Pharmaceutical Leadership Awards 2011 organised by Pharma Leaders, India’s leading
pharma magazine and the Indo-American Chamber of Commerce
2010

18. Best Policy Holder Award
Ranbaxy bags the Best Policy Holder Award in the category of Best
Compliance Practices
Reader’s Digest Trusted Brand
Revital is recognised as the ‘Reader’s Digest Trusted Brand’ in the
Health & Personal Care (Vitamin/ Health Supplements) category in 2010. Revital
receives the exclusive gold award in the category
Nigerian Awards for Roscillox and Gestid
The Institute of Direct Marketing of Nigeria recognises Ranbaxy’s
Roscillox suspension as the most effective and preferred antibiotic in its segment. Gestid
bags the Excellence Award in the category of Antacid Brand of the Year from the Institute
of Brand Management, Nigeria
SammanPatra
Ranbaxy’s plant in Dewas, Madhya Pradesh, India receives the
‘SammanPatra’ for being ranked 2nd in the category for contribution towards service tax
Thompson Reuters Innovation Award

19. Ranbaxy is felicitated with the Thompson Reuters Innovation Award,
in recognition of being India’s Most Innovative Pharma Corporate Enterprise for the year
2010
No. 1 in the Generics Category
Ranbaxy is ranked No. 1 in the Generics category in improving access to needed
medicines in a study in 2010 by Access to Medicine (ATM) foundation, a Netherlands-
based non-profit organisation which is an initiative to improve access to medicines
worldwide
2009
Outstanding Contribution to the Pharmaceutical Industry
Ranbaxy is recognised for its ‘Outstanding Contribution to the
Pharmaceutical Industry’ by Pharmexcil, India
2007
Most Respected Company of the Year
Ranbaxy is ranked No. 1 in the pharma sector in the Most Respected Companies Survey
by Business World, India’s leading business magazine
Most Innovative Company of the Year
Ranbaxy is recognised as one of the Most Innovative Companies in a survey by Business
Today, a leading business magazine in India
Largest Employer of the Year in the Pharmaceutical Industry

20. NJBIZ, the leading business publication in New Jersey, recognises Ranbaxy as one of the
largest employers in the pharmaceutical industry in the state of New Jersey in the US
Marketing Excellence Award for Volini
Organisation of Pharmaceutical Producers of India (OPPI) selects Ranbaxy’s leading
brand Volini for the Marketing Excellence Award 2007 in the new product category
IPA Bilcare Award for Packaging
Ranbaxy wins the IPA Bilcare Award for its ‘Twin pocket nested pouch’ developed by the
R&D Packaging Team
Pharma Excellence Award
Ranbaxy is felicitated with the Pharma Excellence Award for
‘Leveraging Global Opportunity’ by the Express Pharma Group. It is lauded for creating a
niche for itself in the most competitive global pharmaceutical industry
2006
Prestigious Private Label Supplier of the Year Award
Ranbaxy’s US subsidiary, Ohm Labs receives the prestigious Private Label Supplier of the
Year Award from AmerisourceBergen, one of the world’s largest pharmaceutical services
companies serving the US, Canada and other select markets
National Award for Excellence in Water Management
Ranbaxy’s manufacturing plant in Toansa, Punjab, India receives the
National Award for Excellence in Water Management 2005 for being an ‘Excellent Water

21. Efficient Unit’
Ranbaxy Russia – Company of the Year Award
Ranbaxy Russia is bestowed with the ‘Profession is Life – Company of the Year Award’ in
the category of ‘Manufacture and Promotion of Medical Goods and Services’ in 2006
Most Consistent Wealth Creator
Ranbaxy is honoured in India as the nation’s ‘Most Consistent Wealth Creator’ by
MotilalOswal Securities, for the period 1991-2006. The Annual Wealth Creation Study
identifies the top 100 wealth creators amongst companies that have added at least Rs. 1
billion to their market capitalisation during the period 2000-06
Terapia Ranbaxy Awarded European Health 2006 Trophy
Reader’s Digest awards Terapia Ranbaxy the European Health 2006 Trophy for
Excellence in Communication
2005
US Subsidiary Receives Supplier Quality Award
Ranbaxy’s US subsidiary receives the Supplier Quality Award from Cardinal Health, the
second largest wholesaler in the US
US Subsidiary Receives the Supplier Award from Walmart
Ranbaxy’s US subsidiary receives the prestigious Supplier Award from
Walmart, the largest chain store in the US, for outstanding performance in the first
quarter of 2005
Amity Global Corporate Excellence Award
Ranbaxy receives the Amity Global Corporate Excellence Award as a recognition of its
best practices

22. Ranbaxy among India’s Best Managed Companies of the year
Ranbaxy is featured in the elite group of India’s Best Managed
Companies in a survey conducted by Business Today, the largest-circulated business
fortnightly in India
2004
Pharma Pulse Award
Ranbaxy receives ‘Pharma Pulse Award’ for being the best exporter of
the year
Yanhcheng Friendship Award
Ranbaxy Guangzhou China Limited wins the Yanhcheng Friendship
Award for its contribution to the local economy and the development of the society of
Guangzhou, China
National Award for excellence in Energy Management
Ranbaxy’s manufacturing facility in Toansa, Punjab, India wins the
National Award for Excellence in Energy Management
Business of the Year Award

23. Ranbaxy and Ohm Labs bag the prestigious ‘Business of the Year Award’ from Brunswick
Chamber of Commerce, US
Indiastar Award
Ranbaxy receives the prestigious Indiastar Award of the Year for Best
Packaging
Greentech Environment Excellence Award
Ranbaxy’s plant in Toansa, Punjab, India bags the prestigious
‘Greentech Environment Excellence Silver Award’ in the pharma sector for the year
2003-04. The awards are given away by the Greentech Foundation, a Non
GovernmentalOrganisation
Frost & Sullivan Entrepreneurial Company of the Year
Ranbaxy Brazil bags the prestigious Entrepreneurial Company of the Year Award from
Frost & Sullivan
Frost & Sullivan Award 2004
Ranbaxy US receives the Frost & Sullivan Award 2004 for Customer Value
2003
ET (The Economic Times) Award

24. Ranbaxy receives the ‘ET Award for Best Performing Company of the
Year’ from The Economic Times, India’s largest business newspaper
Best Exporter Award
Ranbaxy bags the CONCOR (Container Corporation of India) Best
Exporter Award for the year 2002-03 in the air exports category
Top Products of Ranbaxy
Molecule Drug Class
Atorvastatin & Combinations Hypolipidemics
Donepezil Anti-Alzheimer’s
Valacyclovir Anti-Virals
Simvastatin Hypolipidemics
Amoxicillin+Clavulanic Acid Anti-bacterials
Ketorolac Analgesics
Ciprofloxacin & Combinations Anti-bacterials
Imipenem + Cilastatin Anti-bacterials
Loratadine& Combinations Anti-histaminics
Fenofibrate& Combinations Hypolipidemics

25. Amoxicillin & Combinations Anti-bacterials
Cephalexin Anti-bacterials
Clarithromycin Anti-bacterials
Ambazone Oral Antiseptics
Pantoprazole & Combinations Proton Pump Inhibitor

26. Quality Leadership and Excellence by Design
At Ranbaxy, our mission is to provide trusted medicines that help people lead healthier
lives. The philosophy and intent are to create and maintain world-class business
practices to ensure that our products are safe, effective and compliant with all
internationally defined good practices. The passion for quality goes beyond business and
statutory requirements. The only one focus – Patients.
Their commitment to implementing a robust, global quality management system is based
upon our desire to sustain a culture of operational excellence, meeting and exceeding the
expectations of all stakeholders, including patients, customers and Government
regulators.
They are committed to fulfilling the spirit and intent of our Global Quality Philosophy at
all locations where we conduct regulated research, development, manufacture, testing
and/or distribution of pharmaceutical products. Their objective is sustained compliance
with internationally defined good practices, collectively known as GxP. This includes
Good Manufacturing Practice (GMP), Good Clinical Practice (GCP), Good Laboratory
Practice (GLP), Good Distribution Practice (GDP) and Good Pharmacovigilance Practice
(GPVP).
The commitment to GxP regulatory excellence supports our objective of providing safe
and efficacious pharmaceutical products to our customers worldwide. Alignment with
these standards provides the assurance that patient safety is protected and that the data
provided to the regulators is of the highest accuracy, integrity and quality.
Quality Mission Statement
Ranbaxy partner’s with their stakeholders to assure high quality development,
manufacture and distribution of reliable and safe medicines through:
Qualified, responsible, and motivated employees
Integrity of theirbehaviour and actions
Effective and efficient GxP compliant quality systems
Continuous quality improvement

27. Quality Management Principles
Each of them is dedicated to contributing to the process of developing, manufacturing
and distributing the company’s medicines in a manner that meets the safety, efficacy and
compliance expectations of both customers and Government regulators.
They adhere to the following principles when implementing our Global Quality Policy:
Individual Responsibility – Quality is a part of our culture at Ranbaxy. Every employee is
focused on quality
Management Responsibility – Management allocation of appropriate resources for
effective implementation of all required quality management systems designed to
support and sustain a culture of continuing GxP compliance and operational excellence
Accuracy and Ethics – Every employee shall generate and accurately document all
required quality data in accordance with the highest ethical standards and Ranbaxy’s
Code of Conduct principles
Continuous Improvement – Quality performance indicators shall be measured and
assessed with outcomes designed to drive continuous improvement in our quality
systems and employee performance
Quality Organisation Structure
The global quality organisation is independently structured and resourced to
fulfilorganisational responsibilities and global objectives as defined by our quality
management system to ensure the achievement of established product quality standards.
Quality System Management
The quality system comprises both Quality System Controls and Quality Management
Controls.
Quality System Controls
Quality System Controls assure that the development, manufacture, release and
distribution of drug products take place through well-defined and well-documented
quality systems and procedures.
Key elements for Quality System Controls include:
Facilities and Equipment System
Materials System
Production System
Packaging and Labelling System
Laboratory Controls Systems
Quality Systems
Quality Management Controls
Quality Management Controls enable us to proactively analyse and manage the

28. performance of our global quality system. Our Quality Management Controls include
QA/GxP processes for:
Resource Management
Employee Training
Quality and Compliance Data Trending and Analysis
Quality System Management Reviews
GxP Document Management
Our global document management hierarchy is outlined in the pyramid shown below:
Inclusive and Motivating Principles
Ranbaxy ensure’s that the processes of our business partners comply with national and
international regulatory standards that are in alignment with those of their own. They
have implemented a well-defined and thoroughly documented set of quality systems and
procedures for our business partners.
Quality means continuous improvement. Our Global Quality Standards are constantly
benchmarked against best practices and so these are continually upgraded to keep pace
with the changing dynamics of the global environment.
They remain committed to the highest levels of professionalism and integrity and will
ensure that all our facilities continue to meet the exemplary standards that are expected
of a global pharmaceutical company

29. GDP
% average annual GDP growth
1900 – 1950 1.0
1950 – 1980 3.5
1980 – 2002 6.0
2002 – 2006 8.0
2002-2012 UPTO 8.1

30. COMPARISON OF RANBAXY WITH OTHER
COMPANIES
CONCLUSION
With a couple of sentences, I would like to
address you that Ranbaxy Pharmaceutical Company

31. is growing on a larger scale. It has many
benefits and profits which will be coming in the
future years.
Therefore, I would like to conclude that I
thoroughly enjoyed working on this company as my
assignment.